Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

A at week 20 of post-treatment follow-up. Of the remaining 8 patients enrolled in Arm D, 4 discontinued due to adverse events prior to week 12, and 4 did not achieve RVR.

Interim 12-Week Safety Analysis of PROVE 1

In PROVE 1, the types of adverse events that have been commonly observed with interferon and ribavirin were seen across all treatment arms. The most common adverse events, regardless of treatment assignment, were fatigue, rash, headache and nausea. Gastrointestinal disorders, rash and anemia were more common in the telaprevir arms.

In the telaprevir dosing arms, the incidence of treatment discontinuations due to adverse events through 12 weeks was 11% (19 of 175 patients), compared to 3% (2 of 75 patients) in the control arm. The difference between the two groups is due to the greater number of discontinuations due to rash, gastrointestinal disorders and anemia in the telaprevir arms compared to the control arm. The most common reason for treatment discontinuation in the telaprevir arms was rash (7 patients), and the median time to discontinuation in these patients was 64 days.

Webcast of Investor Presentation

Vertex intends to provide a live webcast of its investor presentation from Barcelona beginning at 7:30 p.m. CEST (1:30 p.m. EDT) on Saturday, April 14. The presentation may be accessed from the 'Events Calendar' on the homepage of Vertex's website at www.vrtx.com. A replay of the webcast will also be available on the Company's website until April 27, 2007. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

About Telaprevir (VX-950)

Telaprevir (VX-950) is an investigational oral inhibitor of HCV protease, an enzyme essential for viral replication, and is one of the most advanced investigational agents in development that specifically targets HCV. Vertex is conducting a global Phase 2b clinical development program for telaprevir consis
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:3/5/2015)... N.Y. , March 5, 2015  AMRI (NASDAQ: ... Pettersson , fills the newly created position of VP ... Christopher Conway , Senior Vice President of Global Sales ... Pettersson will lead the international sales team in an ... share in targeted market segments. Mr. Pettersson will drive ...
(Date:3/5/2015)... 2015 LUNGevity Foundation, the nation,s leading ... Administration,s (FDA) approval of Bristol Myers Squibb,s new ... treatments add another critical new treatment option to ... a patient,s own immune system to fight cancerous ... for patients with squamous cell lung cancer, a ...
(Date:3/5/2015)... DUBLIN , Mar. 05, 2015 Research ... announced the addition of the "Global Pharma ... and Cost Optimization Plays Major Role In Shaping ... report to their offering. Strategy ... resulting in healthy Cash position- Will accelerate Next ...
Breaking Medicine Technology:AMRI Hires VP of International Sales 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 3Global Pharma US & EU Outlook 2015: First -In-Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies 2Global Pharma US & EU Outlook 2015: First -In-Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies 3
... Company to Submit a Supplemental New Drug Application to ... Cephalon, Inc . (Nasdaq: CEPH ... clinical trial of NUVIGIL(R) (armodafinil) Tablets [C-IV] as a ... Based on these findings, Cephalon(R) will file a ...
... today announced that the Endocrinologic and Metabolic Drugs Advisory Committee ... finalized its discussions of questions related to liraglutide, a once-daily ... to the risk profile of liraglutide. , , ... A majority of Advisory Committee members supported that appropriate evidence ...
Cached Medicine Technology:Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 2Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 3Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 4Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes 2Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes 3
(Date:3/5/2015)... March 05, 2015 At the ... Beyond,” leaders in addiction treatment met today in Jackson, ... best clinical practices. Among the numerous respected speakers will ... will address the role that pain medications have had ... evidence-based treatment options. , "It is hard to believe ...
(Date:3/5/2015)... Taking center stage at the Fort ... 9-11th is IDRevolution hosted by IDLife LLC, a ... IDLife offers a variety of nutritional products including ... to vitamin supplementation is based upon the latest ... compliant online assessment and ends with a truly ...
(Date:3/5/2015)... Harrisburg, NC (PRWEB) March 05, 2015 ... of Physician Assistants’ (AAPA) review of Clearstream, ... AAPA determined that Clearstream’s MediDefense line of products—led ... of the AAPA’s Affinity Partner Program. , The ... physician assistants across all medical and surgical specialties ...
(Date:3/5/2015)... Jordan, Utah (PRWEB) March 05, 2015 ... defibrillator by LifeVest® as a treatment option for sudden ... continuously monitors heart rhythm and can detect any life-threatening ... device will alert the patient before delivering a treatment ... , Dr. Adam Elhaddi of Jordan Valley Medical Center ...
(Date:3/5/2015)... 05, 2015 Altec Products, Inc., a ... today their participation in the Houston, TX and Charlotte, ... Inspire Tour will unite Sage enterprise resource planning (ERP) ... workable solutions to real-world business challenges. , The ... Plaza Houston Galleria Area on March 10th. The Charlotte, ...
Breaking Medicine News(10 mins):Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:IDLife Partners John C. Maxwell and Troy Aikman speaking at IDRevolution in Fort Worth, TX April 9th-11th, 2015 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:New Technology Behind LifeVest® Wearable Defibrillator Saves the Life of Utah Man in Cardiac Arrest 2Health News:New Technology Behind LifeVest® Wearable Defibrillator Saves the Life of Utah Man in Cardiac Arrest 3Health News:Altec Attends Sage Inspire Tour Stops in Houston and Charlotte to Showcase Sage ERP Document Management and Workflow Solution 2Health News:Altec Attends Sage Inspire Tour Stops in Houston and Charlotte to Showcase Sage ERP Document Management and Workflow Solution 3
... worlds largest publisher of open access journals, is ... Magnetic Resonance (JCMR) is moving to BioMed Centrals ... publishers, Taylor & Francis. The move from a ... Society of Cardiovascular Magnetic Resonance (SCMR) members and ...
... OCALA, Fla., Dec. 12 Franck,s Compounding Lab ... Pharmacy Services in,Woodruff, Wisconsin. Island Pharmacy owners, Randy ... other personal interests. Selling their,pharmacy to Franck,s Compounding ... ensure the continuance of high quality prescriptions and ...
... up with community based, organizations and Babies "R" Us to help ... ... little ones, MERRILLVILLE, Ind., Dec. 12 With a traditional ... afternoon when,Anthem Blue Cross and Blue Shield hosts a community-wide baby ...
... fighting gum disease , , WEDNESDAY, Dec. 12 (HealthDay ... infections, and a weakened immune response may be to ... , In experiments with mice infected with the bacteria ... to battle gum infection than their normal-weight counterparts, according ...
... Austria, December 12 f-star, an antibody,engineering company ... unique Modular Antibody Technology, announced today that it,has ... three,outstanding scientists to form the nucleus of this ... Professor Sir Ravinder Maini, Imperial College, London, ...
... organizations in ... underserved areas, WOODLAND HILLS, Calif., Dec. 11 ... $30,000 in end of,year donations to various food banks throughout California. An ... and,southern California to assist vulnerable populations., Blue Cross employees will visit ...
Cached Medicine News:Health News:Society of Cardiovascular Magnetic Resonance chooses open access 2Health News:Anthem Blue Cross and Blue Shield Celebrates Local Moms-to-Be at Community Baby Shower 2Health News:Anthem Blue Cross and Blue Shield Celebrates Local Moms-to-Be at Community Baby Shower 3Health News:Obesity Weakens Immune Response 2Health News:Antibody Engineering Company f-star Appoints Three Pioneers in Antibody Engineering and Development to its Newly Established Scientific Advisory Board 2Health News:Antibody Engineering Company f-star Appoints Three Pioneers in Antibody Engineering and Development to its Newly Established Scientific Advisory Board 3Health News:Blue Cross of California Gives $30,000 in Holiday Donations to Food Banks Throughout the State 2
Williger periosteal elevator, 6 1/4", sharp, 5 mm wide....
Sedillot periosteal elevator, 16 mm, sharp, 7"....
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Periosteal elevator #9H, 17.5 cm, 7"....
Medicine Products: